Characterization of EGFR family gene aberrations in cholangiocarcinoma

Oncology Reports

Volumn 32, Issue 2, 2014, Pages 700-708

  Yang, Xiaoqing ^a   Wang, Weishan ^b   Wang, Chunni ^a   Wang, Lin ^a,c   Yang, Muyi ^a   Qi, Mei ^a   Su, Hong ^a   Sun, Xiubin ^d   Liu, Zhiyan ^a   Zhang, Juan ^e   Qin, Xiaomin ^e   Han, Bo ^a,e  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Yishui Central Hospital   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^d SHANDONG UNIVERSITY   (China)

^e SHANDONG UNIVERSITY   (China)

Author keywords

Cholangiocarcinoma; EGFR; HER2; HER4; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4;

AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; EXTRAHEPATIC CHOLANGIOCARCINOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC DISORDER; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; TUMOR LOCALIZATION; TUMOR VOLUME; BILE DUCT TUMOR; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; INTRAHEPATIC BILE DUCT; MCF 7 CELL LINE; METABOLISM; MIDDLE AGED; PATHOLOGY; SURVIVAL; TUMOR CELL LINE;

AGED; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MCF-7 CELLS; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS;

EID: 84903200619     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3261     Document Type: Article

References (40)

1. Malhi H and Gores GJ: Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 45: 856-867, 2006. (Pubitemid 44646688)
2. Khan SA, Thomas HC, Davidson BR and Taylor-Robinson SD: Cholangiocarcinoma. Lancet 366: 1303-1314, 2005. (Pubitemid 41416587)
3. Anderson C and Kim R: Adjuvant therapy for resected extrahepatic cholangiocarcinoma: a review of the literature and future directions. Cancer Treat Rev 35: 322-327, 2009.
4. Zhang H, Berezov A, Wang Q, et al: ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 117: 2051-2058, 2007. (Pubitemid 47224766)
5. Zaczek A, Brandt B and Bielawski KP: The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol Histopathol 20: 1005-1015, 2005. (Pubitemid 40932618)
6. Verma S, Miles D, Gianni L, et al: Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367: 1783-1791, 2012.
7. Franklin WA, Veve R, Hirsch FR, Helfrich BA and Bunn PA Jr: Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 29: 3-14, 2002. (Pubitemid 34226514)
8. Suo Z, Risberg B, Kalsson MG, et al: EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 196: 17-25, 2002.
9. Wei Q, Shui Y, Zheng S, et al: EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: Implications for targeted radionuclide therapy. Oncol Rep 25: 3-11, 2011.
10. Awaya H, Takeshima Y, Furonaka O, Kohno N and Inai K: Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung. J Clin Pathol 58: 1076-1080, 2005. (Pubitemid 41416058)
11. Harder J, Waiz O, Otto F, et al: EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol 15: 4511-4517, 2009.
12. Jaiswal BS, Kljavin NM, Stawiski EW, et al: Oncogenic ERBB3 mutations in human cancers. Cancer Cell 23: 603-617, 2013.
13. Fujiwara S, Ibusuki M, Yamamoto S, Yamamoto Y and Iwase H: Association of ErbB1-4 expression in invasive breast cancer with clinicopathological characteristics and prognosis. Breast Cancer: Oct 26, 2012 (Epub ahead of print).
14. Memon AA, Sorensen BS, Melgard P, Fokdal L, Thykjaer T and Nexo E: Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients. Br J Cancer 91: 2034-2041, 2004. (Pubitemid 40128770)
15. Yoshikawa D, Ojima H, Iwasaki M, et al: Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 98: 418-425, 2008. (Pubitemid 351161240)
16. Kim HJ, Yoo TW, Park DI, et al: Gene amplification and protein overexpression of HER-2/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: its prognostic implication in nodepositive patients. Ann Oncol 18: 892-897, 2007. (Pubitemid 47054087)
17. Shafizadeh N, Grenert JP, Sahai V and Kakar S: Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder. Hum Pathol 41: 485-492, 2010.
18. Lubner SJ, Mahoney MR, Kolesar JL, et al: Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol 28: 3491-3497, 2010.
19. Lee HJ, Chung JY, Hewitt SM, Yu E and Hong SM: HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma. Virchows Arch 461: 521-530, 2012.
20. Jarnagin WR, Klimstra DS, Hezel M, et al: Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol 24: 1152-1160, 2006. (Pubitemid 46638813)
21. Edge SB and Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17: 1471-1474, 2010.
22. Wang L, Zhang J, Yang X, et al: SOX4 is associated with poor prognosis in prostate cancer and promotes epithelial-mesenchymal transition in vitro. Prostate Cancer Prostatic Dis 16: 301-307, 2013.
23. Rajkumar T, Stamp GW, Pandha HS, Waxman J and Gullick WJ: Expression of the type 1 tyrosine kinase growth factor receptors EGF receptor, c-erbB2 and c-erbB3 in bladder cancer. J Pathol 179: 381-385, 1996. (Pubitemid 26276106)
24. Ito Y, Takeda T, Sasaki Y, et al: Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma. Pathol Res Pract 197: 95-100, 2001. (Pubitemid 32194502)
25. Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y and Ooi A: Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol 206: 356-365, 2005. (Pubitemid 40903200)
26. Endreffy E, Burg K, Gyurkovits K, Kalman M, Laszlo A and Rasko I: Allele frequencies of cystic fibrosis-linked markers and F508 deletion in affected Hungarian families. Acta Paediatr Hung 32: 101-113, 1992.
27. Ruys AT, Groot Koerkamp B, Wiggers JK, Klumpen HJ, Ten Kate FJ and van Gulik TM: Prognostic biomarkers in patients with resected cholangiocarcinoma: a systematic review and meta-analysis. Ann Surg Oncol 21: 487-500, 2013.
28. Lee J, Park SH, Chang HM, et al: Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 13: 181-188, 2012.
29. Chiorean EG, Ramasubbaiah R, Yu M, et al: Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101. Oncologist 17: 13, 2012.
30. Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF and Bundred NJ: Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res 11: 2163-2168, 2005. (Pubitemid 40490173)
31. Edwards J, Traynor P, Munro AF, Pirret CF, Dunne B and Bartlett JM: The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. Clin Cancer Res 12: 123-130, 2006. (Pubitemid 43166185)
32. Thybusch-Bernhardt A, Beckmann S and Juhl H: Comparative analysis of the EGF-receptor family in pancreatic cancer: expression of HER-4 correlates with a favourable tumor stage. Int J Surg Investig 2: 393-400, 2001.
33. Bussu F, Ranelletti FO, Gessi M, et al: Immunohistochemical expression patterns of the HER4 receptors in normal mucosa and in laryngeal squamous cell carcinomas: antioncogenic significance of the HER4 protein in laryngeal squamous cell carcinoma. Laryngoscope 122: 1724-1733, 2012.
34. Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD and Lunec J: Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 57: 3272-3280, 1997. (Pubitemid 27351746)
35. Rickert CH: Prognosis-related molecular markers in pediatric central nervous system tumors. J Neuropathol Exp Neurol 63: 1211-1224, 2004. (Pubitemid 39603393)
36. Settakorn J, Kaewpila N, Burns GF and Leong AS: FAT, E-cadherin, β catenin, HER 2/neu, Ki67 immuno-expression, and histological grade in intrahepatic cholangiocarcinoma. J Clin Pathol 58: 1249-1254, 2005. (Pubitemid 41752767)
37. Buchler P, Reber HA, Buchler MC, et al: Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin). J Gastrointest Surg 5: 139-146, 2001. (Pubitemid 33652051)
38. Reschke M, Mihic-Probst D, van der Horst EH, et al: HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res 14: 5188-5197, 2008.
39. Yi ES, Harclerode D, Gondo M, et al: High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. Mod Pathol 10: 142-148, 1997. (Pubitemid 27110039)
40. Begnami MD, Fukuda E, Fregnani JH, et al: Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol 29: 3030-3036, 2011.